San Bruno, CA. May 21, 2015. PRC Clinical, the Clinical Trial Management CRO, is officially joining the Alliance for Regenerative Medicine (ARM). The ARM counts more than 200 pioneering organizations, fostering research, development, investment, and commercialization of transformational treatments and cures for patients worldwide.
PRC Clinical, the California-based CRO focused in Clinical Trial Management, has developed a strong expertise in stem cell and regenerative research working with sponsors in the United States and Israel. “We believe regenerative medicine holds exciting potential to resolve unmet medical needs of untreatable diseases and possibly ease the burdens of an aging population” states Curtis Head, CEO at PRC Clinical. “Joining ARM is one more way for PRC to express our commitment to developing highly innovative therapies for the human condition and beyond.”
Regenerative Medicine is focused on the development and application of cell-based therapies and related technologies to enhance the natural healing process, and/or replace or regenerate organs and tissues. Delivering cures through regenerative medicine requires coordination amongst a broad range of stakeholder groups from industry, academia, government, healthcare professionals, the investment community and consumer advocates. ARM members include leading pharmaceutical companies such as Pfizer, Johnson & Johnson and Novartis, as well as innovative life science companies, research institutions, capital providers, foundations, associations, and patient advocates.
PRC Clinical will attend ARM’s 2015 Stem Cell Meeting on the Mesa on October 7-9 2015 in La Jolla, California. This annual meeting attracts more than 800 industry-leading professionals for partnering opportunities, interactive panels, and scientific lectures.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.